文献速递肝肾功能剂量调整药物相互作用

硼替佐米临床药代动力学与药效学

Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

本文综述硼替佐米在不同剂量、给药途径及特殊人群中的临床药代动力学与药效学,并讨论其疗效与安全性。静脉给药呈二室模型,皮下与静脉暴露等效;中重度肝损伤需减量起始,肾功能不全不影响固有药代动力学;CYP3A4强诱导剂或抑制剂可改变全身暴露。

要点

  • 皮下与静脉给药全身暴露等效,20S蛋白酶体抑制药效学相似。
  • 肾功能不全不影响硼替佐米固有药代动力学。
  • 中重度肝损伤患者血浆浓度升高,应减量起始。

核心结论

  • 硼替佐米皮下与静脉给药的全身暴露等效,20S蛋白酶体抑制的药效学参数也相似。
  • 中重度肝损伤可使硼替佐米血浆浓度升高,这类患者应以减量剂量起始。
  • 硼替佐米经CYP3A4和CYP2C19广泛代谢,强CYP3A4诱导剂或抑制剂可改变其全身暴露。

研究设计与样本

  • 本文为综述, critically 回顾并总结硼替佐米在不同剂量水平、给药途径及特定患者亚群中的临床药代动力学与药效学。
  • 文章同时讨论硼替佐米的临床疗效与安全性。

主要发现

  • 静脉硼替佐米的药代动力学特征为二室模型,初始分布相快速,随后消除相较长,表观分布容积大。
  • 比较皮下与静脉硼替佐米的研究显示,两种途径的全身暴露等效,20S蛋白酶体抑制的药效学参数也相似。
  • 肾功能不全不影响硼替佐米的固有药代动力学。
  • 中重度肝损伤导致硼替佐米血浆浓度升高。

关键数值与推荐

  • 中重度肝损伤患者应以减量剂量起始硼替佐米治疗。
  • 强CYP3A4诱导剂或抑制剂可改变硼替佐米的全身暴露。

临床怎么用

  • 临床选择皮下或静脉给予硼替佐米时,可依据暴露等效性及药效学相似性进行决策。
  • 对中重度肝损伤患者,起始硼替佐米时应减量。
  • 合并使用强CYP3A4诱导剂或抑制剂时,应关注硼替佐米全身暴露可能改变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proteasome inhibitors disrupt multiple pathways in cells and the bone marrow microenvironment, resulting in apoptosis and inhibition of cell-cycle progression, angiogenesis, and proliferation. Bortezomib is a first-in-class proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma after one prior therapy. It is also effective in other plasma cell disorders and non-Hodgkin lymphomas. The main mechanism of action of bortezomib is to inhibit the chymotrypsin-like site of the 20S proteolytic core within the 26S proteasome, thereby inducing cell-cycle arrest and apoptosis. The pharmacokinetic profile of intravenous bortezomib is characterized by a two-compartment model with a rapid initial distribution phase followed by a longer elimination phase and a large volume of distribution. Bortezomib is available for subcutaneous and intravenous administration. Pharmacokinetic studies comparing subcutaneous and intravenous bortezomib demonstrated that systemic exposure was equivalent for both routes; pharmacodynamic parameters of 20S proteasome inhibition were also similar. Renal impairment does not influence the intrinsic pharmacokinetics of bortezomib. However, moderate or severe hepatic impairment causes an increase in plasma concentrations of bortezomib. Therefore, patients with moderate or severe hepatic impairment should start at a reduced dose. Because bortezomib undergoes extensive metabolism by hepatic cytochrome P450 3A4 and 2C19 enzymes, certain strong cytochrome P450 3A4 inducers and inhibitors can also alter the systemic exposure of bortezomib. This article critically reviews and summarizes the clinical pharmacokinetics and pharmacodynamics of bortezomib at various dosing levels and routes of administration as well as in specific patient subsets. In addition, we discuss the clinical efficacy and safety of bortezomib.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Tan CRC, Abdul-Majeed S, Cael B, et al. Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. Clin Pharmacokinet. 2019. PMID: 29802543. doi:10.1007/s40262-018-0679-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。